"Designing Growth Strategies is in our DNA"
Brain Metastasis is a tumor associated with brain that starts in another part of the body and later spreads to the brain. Brain metastasis is secondary brain tumors and are more common than primary brain cancer. The types of cancer that are likely to spread to the brain are lung, breast, colon, melanoma, and kidney. As the brain metastatic tumor grows, it creates pressure and changes the function of the surrounding brain tissue. Symptoms include headache, swelling, vomiting, increasing memory problems, dizziness, and others.
Management and treatment for brain metastasis include medication, surgery, chemotherapy, targeted therapy, and radiation. Corticosteroids and anticonvulsants are generally prescribed for the treatment of brain tumors. Drugs like Bevacizumab, Carmustine, and Lomustine, are the drugs used to treat glioblastoma, high-grade glioblastoma, and other brain tumors.
Pharmaceutical companies, along with various research institutes, have been focusing on studying and developing new treatment options for brain metastasis. For instance; LY3381916, studied by Eli Lilly and Company is currently in phase-1 clinical trials for the study of safety and efficacy of LY3381916 drug when administered alone or with combination with other drugs in patients with brain metastasis.
To know how our report can help streamline your business, Speak to Analyst
At present around 53% of the pipeline candidates for brain metastasis are in the phase-2 clinical stage. Maximum studies are sponsored by research institutes.
The report on ‘Brain Metastasis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Brain Metastasis The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Brain Metastasis.
The report on ‘Brain Metastasis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.